Experts at UT MD Anderson have numerous presentations throughout the 2026 AACR Annual Meeting. All times listed in Pacific Time.
Experts at UT MD Anderson have numerous presentations throughout the 2026 AACR Annual Meeting. All times listed in Pacific Time.
Friday, April 17
MW01 — AI in cancer care: Practical applications transforming oncology
3–4:30 p.m.
Room 29 | Upper Level Convention Center
Chair introduction
Speaker: Caroline Chung, M.D.
Embracing cancer complexity with data and AI in context
3:01–3:21 p.m.
Speaker: Caroline Chung, M.D.
Saturday, April 18
ED21 — CAR T therapy: Transforming the landscape of adult and pediatric blood cancers
8–9:30 a.m.
Room 6 CF │Upper Level Convention Center
CAR T cell therapy in myeloma: Durability, design and path to functional cure
8:20–8:40 a.m.
Speaker: Krina Patel, M.D.
ED46 — Advances in pre-metastatic niche biology: From pre-clinical insights to clinical opportunities
8–9:30 a.m.
Ballroom 20 AB │Upper Level Convention Center
Disrupting the "soil": Exploring and targeting the pre-metastatic niche
8:31–8:51 a.m.
Speaker: Dihua Yu, M.D, Ph.D.
ED52 — Mapping neural-immune circuits: Spatial multi-omics in the tumor microenvironment
10–11:30 a.m.
Ballroom 6 CF │Upper Level Convention Center
Chair introduction
Speaker: Moran Amit, M.D., Ph.D.
Translating spatial multiomics into clinical action: Integration of spatial, clinical, and population data
11:03–11:16 a.m.
Speaker: Moran Amit, M.D., Ph.D.
MW03 — Bayesian and model-assisted designs for early-phase clinical trials—Simplicity meets efficiency
10–11:30 a.m.
Room 5 │Upper Level Convention Center
Chair/Introduction
Speaker: Ying Yuan, Ph.D.
Bayesian designs for safety and futility monitoring in early-phase clinical trials
11–11:20 a.m.
Speaker: Ying Yuan, Ph.D.
CTMS01 — Updates in anticancer immunotherapies
10 a.m.–noon
Ballroom 6 A │Upper Level Convention Center
Abstract CT002: First-in-human Phase I study of PLN-101095, a first-in-class dual αvβ8/αvβ1integrin inhibitor, as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors refractory to immune checkpoint inhibitors (ICI)
10:20–10:30 a.m.
Presenter: Timothy Yap, M.B.B.S., Ph.D.
DC01 — Where expedited pathways, innovation, safety and patient access collide: A KRAS case study
12:30–2 p.m.
Room 1 │Upper Level Convention Center
Co-Moderator: Timothy Yap, M.B.B.S., Ph.D.
CTMS02 — Aiming for cure: Perioperative clinical trials
12:30–2:30 p.m.
Ballroom 6 A │Upper Level Convention Center
Abstract CT012: A Phase II single-arm open-label trial evaluating zanidatamab in patients with early stage HER2-positive breast cancer: The NeoZanHER study
12:51–1:01 p.m.
Presenter: Funda Meric-Bernstam, M.D.
Abstract CT015: Clinical outcomes by genomic markers and ctDNA dynamics with perioperative nivolumab (NIVO) for resectable NSCLC from CheckMate 77T
1:36–1:46 p.m.
Presenter: Tina Cascone M.D., Ph.D.
MW05 — Deep learning in digital pathology: From morphology to multimodal biomarkers
2:30–4 p.m.
Ballroom 6 CF │Upper Level Convention Center
AI pathology meets spatial omics: Decoding tissue architecture for biomarkers
3:30–3:50 p.m.
Speaker: Linghua Wang, M.D, Ph.D.
Sunday, April 19
AOS01 — Advances in bladder cancer research and treatment: Pathways to precision medicine
1–2:30 p.m.
Room 11 | Upper Level Convention Center
Advances in risk stratification and appropriate management of non-muscle invasive bladder cancer
1:05–1:25 p.m.
Speaker: Ashish Kamat, M.D., M.B.B.S.
AOS13 — Gastric/gastroesophageal cancer dynamics: Pre-cancer evolution, metastasis, microenvironment and therapeutic breakthroughs
1–2:30 p.m.
Room 33 | Upper Level Convention Center
Molecular heterogeneity in primary vs metastases and advances in HER2-directed therapeutics
1:50–2:10 p.m.
Speaker: Jaffer Ajani, M.D.
CTPL01 — New frontiers in precision oncology
1–3 p.m.
Hall H | Ground Level Convention Center
Abstract CT022: First data disclosure of the Phase I trial of the first-in-class combination of WEE1 inhibitor zedoresertib with PKMYT1 inhibitor lunresertib in patients with advanced solid tumors harboring CCNE1, FBXW7 or PPP2R1A genomic alterations
2:00–2:15 p.m.
Presenter: Timothy Yap, M.B.B.S., Ph.D.
CTMS03 — Advanced cellular and immune-based therapeutics
3–5 p.m.
Ballroom 20 AB | Upper Level Convention Center
Abstract CT028: Results of first-in-human, Phase I study of KSQ-001EX, an autologous tumor infiltrating lymphocyte therapy engineered to inactivate the SOCS1 gene, in patients with select advanced solid tumors
3:35–3:45 p.m.
Presenter: Rodabe Amaria, M.D.
MS.BCS01.02 — Integrative computational approaches
3–5 p.m.
Room 30 | Upper Level Convention Center
Abstract 1296: Integrated single cell spatial multi-omics landscape of WHO grades 2-4 diffuse gliomas identifies locoregional metabolomic correlates of glioma plasticity and proliferation
4:05–4:20 p.m.
Presenter: Yanxia Ma, M.D., Ph.D.
Abstract 1297: ADTnorm enables scalable and interpretable single cell proteomics integration across technologies for incorporating historical cancer data
4:20–4:35 p.m.
Presenter: Ye Zheng, Ph.D.
MS.MCB06.01 — Advances in cancer epigenetics
3–5 p.m.
Room 33 | Upper Level Convention Center
Abstract 1361: KDM2A-driven epigenetic reprogramming promotes barrett’s esophagus progression to adenocarcinoma
4:20–4:35 p.m.
Presenter: Shilpa Dhar, Ph.D.
MS.MCB10.01 — Noncoding RNA regulation of cancer hallmarks, therapeutic resistance, and biomarker discovery
3–5 p.m.
Room 15 | Mezzanine Level Convention Center
Abstract 1366: CYP4A22-AS1-YBX1 axis drives radiation resistance in cervical adenocarcinoma via PGK1 transactivation
3:20–3:35 p.m.
Presenter: Mingyi Zhou, M.D.
TM04 — PICR-PSWG town hall
6:30–8 p.m.
Room 28 | Upper Level Convention Center
Chair: Paul Scheet, Ph.D.
Monday, April 20
AT06 — Single cell multi-omic technologies for resolving genotype-phenotype relationships in cancer
10:15–11:45 a.m.
Ballroom 6 B │ Upper Level Convention Center
Chair: Nicholas Navin, Ph.D.
Linking genotypes and phenotypes of single cells to decode breast cancer progression
10:15–10:35 a.m.
Speaker: Nicholas Navin, Ph.D.
SY15 — Immunometabolism in cancer
10:15–11:45 a.m.
Room 29 │ Upper Level Convention Center
Reprogramming NK cell metabolism to enhance adoptive cellular therapy
11:10–11:30 a.m.
Speaker: May Daher, M.D.
AOS03 — Microbiota-host interactions in colorectal cancer development and therapy
12:30–2 p.m.
Room 29 │ Upper Level Convention Center
To be determined
1:25–1:45 p.m.
Speaker: Susan Bullman, Ph.D.
SY08 — Does adherence to oral cancer therapy matter?
12:30–2 p.m.
Room 11 │ Upper Level Convention Center
Patient before pill: Strategies for improving outcomes for standard therapies and clinical trials for colorectal cancer
12:56–1:16 p.m.
Speaker: Van Morris, M.D.
SY11 — Cancer vaccines: The next immunotherapy breakthrough?
12:30–2 p.m.
Ballroom 6 A │ Upper Level Convention Center
NG05 — Mechanisms by which mRNA vaccines augment responses to immune checkpoint blockade
12:55–1:10 p.m.
Speaker: Adam Grippin, M.D., Ph.D.
MG07 — Meet the Editor-in-Chief of Clinical Cancer Research
2–3 p.m.
AACR Publications Booth 3537│Hall BCG
Editor-in-Chief of Clinical Cancer Research
Speaker: Timothy Yap, M.B.B.S., Ph.D.
MS.CL05.01 — Adoptive T cell therapy
2:30–4:30 p.m.
Ballroom 20 AB│Upper Level Convention Center
Abstract 4010: NK-TCR cells: A next-generation platform expanding NK-cell therapeutic potential
3:35–3:50 p.m.
Presenter: Nadima Uprety
MS.IM01.02 — Advances in therapeutic antibodies
2:30–4:30 p.m.
Ballroom 20 CD │Upper Level Convention Center
Abstract 4053: NRP1 drives a novel cross-presentation pathway exploitable by peptide-linked antibodies to redirect viral memory T-cells against solid tumors
3:05–3:20 p.m.
Presenter: Anne Phillips, Ph.D.
MS.CL01.03 — Biomarkers that change management: Predicting therapy benefit, progression and metastatic risk
2:30–4:30 p.m.
Room 29 | Upper Level Convention Center
Abstract 4020: Utility of CA19-9 for prediction of asymptomatic pancreatic cancer among patients with new onset diabetes
3:50–4:05 p.m.
Presenter: Johannes Fahrmann, Ph.D.
MS.ET06.01 — Cracking adaptive resistance: AI-enabled, screen-guided targets in tumor plasticity, DNA damage, metabolism and CTC-associated immunity
2:30–4:30 p.m.
Room 28 | Upper Level Convention Center
Cochair: John Tainer, Ph.D.
Abstract 4033: Chemical trapping of inactive GRB2 dimer unveils a novel cancer vulnerability by coupling replication stress to anti-tumor immunity
2:35–2:50 p.m.
Presenter: Zamal Ahmed, Ph.D.
MS.BCS01.01 — Digital pathology
2:30–4:30 p.m.
Room 31 | Upper Level Convention Center
Abstract 4003: Path-IO: A deep learning pathomics framework for personalized immunotherapy selection and outcome prediction in metastatic non-small cell lung cancer
4:05–4:20 p.m.
Presenter: Rukhmini Bandyopadhyay, Ph.D.
CTMS04 — Focus on ctDNA
2:30–4:30 p.m.
Hall H | Ground Level Convention Center
Chair introduction
2:30–2:35 p.m.
Cochair: Scott Kopetz, M.D., Ph.D.
Abstract CT172: A Phase II trial of adjuvant PD-1 blockade with endocrine therapy in hormone receptor positive inflammatory breast cancer: Circulating biomarkers and molecular correlates of clinical outcomes
3:05–3:15 p.m.
Presenter: Ranjan Upadhyay, M.D., Ph.D.
FO02 — Science of community outreach and engagement: Navigating change and maintaining impact
5–6:30 p.m.
Room 31 │Upper Level - Convention Center
Community engagement as sustainability: The secret sauce for lasting impact
5:20–5:30 p.m.
Speaker: Lorna McNeill, Ph.D.
PDS08 — From hypothesis to headline: Publishing your research
5:30–7:30 p.m.
Harbor Ballroom GH │Manchester Grand Hyatt San Diego
Editor-in-Chief of Clinical Cancer Research
6:15–7:00 p.m.
Speaker: Timothy Yap, M.B.B.S., Ph.D.
TM02 — Immune-driven cancer prevention—From vaccines to lifestyle interventions: A CIMM-CPWG town hall and networking meeting
6:30–8 p.m.
Room 30 │Upper Level Convention Center
Invited speaker: Eduardo Vilar-Sanchez, M.D., Ph.D.
Tuesday, April 21
ADT03 — Synthetic lethality in oncology: Progress made, pitfalls encountered and the path forward
10:15–11:45 a.m.
Room 31 │ Upper Level Convention Center
Chair Introduction
Speaker: Timothy Yap, M.B.B.S., Ph.D.
Targeting synthetic lethal paralogs in the clinic: Progress, pitfalls and the promise
10:40–11:00 a.m.
Speaker: Timothy Yap, M.B.B.S., Ph.D.
AOS07 — Dharma Master Jiantai advances in lung cancer research session: Small cell lung cancers (SCLC) and neuroendocrine cancers (NECs)
10:15–11:45 a.m.
Ballroom 6 B | Upper Level Convention Center
Chair Introduction
Speaker: Lauren Averett Byers, M.D.
On the verge of a watershed for small cell lung cancer and neuroendocrine malignancies
10:40–10:55 a.m.
Speaker: Lauren Averett Byers, M.D.
APRV03 — HPV vaccination and self-sampling for cervical cancer prevention and early detection globally and in underserved settings
10:15–11:45 a.m.
Room 5 | Upper Level Convention Center
To be announced
11:10–11:30 a.m.
Speaker: Jane Montealegre, Ph.D.
AOS10 — Turning the tide in the fight against pancreatic cancer
12:30–2 p.m.
Ballroom 6 A │ Upper Level Convention Center
Recent advances in treatment of pancreatic cancer
12:32–12:47 p.m.
Speaker: Shubham Pant, M.D., M.B.B.S.
SY13 — Off-the-shelf cell therapies for cancer and beyond
12:30–2 p.m.
Room 28 │ Upper Level Convention Center
Off-the-shelf NK cell therapies from biology to the clinic
1–1:20 p.m.
Speaker: Katy Rezvani, M.D., Ph.D.
CTMS05 — Advances in Precision Oncology
2:30–4:30 p.m.
Hall H │ Ground Level Convention Center
Abstract CT303: Safety and efficacy of Elisrasib (D3S-001), a next generation GDP-bound KRAS G12C inhibitor, as monotherapy or combination therapy with cetuximab in previously treated metastatic CRC and PDAC: Results from a Phase I/II study
3:30–3:40 p.m.
Speaker: Kanwal Raghav, M.B.B.S., M.D.
MS.CL05.02 — Immunotherapy: Mechanisms and responses
2:30–4:30 p.m.
Room 28 | Upper Level Convention Center
Cochair: May Daher
Abstract 6743: Peripheral immune profiling from the DIET trial - A randomized double blinded dietary intervention study in melanoma patients receiving immunotherapy
3:20–3:35 p.m.
Presenter: Yufan Qiu, M.D., Ph.D.
MS.CL07.01 — Targeted therapy: Data driven approaches and novel drugs
2:30–4:30 p.m.
Room 31 | Upper Level Convention Center
Abstract 6761: Antitumor activity of datopotamab deruxtecan in a co-clinical trial with patient derived xenografts
3:20–3:35 p.m.
Presenter: Dhruv Chachad, Ph.D.
MS.BCS02.01 — Machine learning approaches for cancer diagnosis and treatment prediction
2:30–4:30 p.m.
Ballroom 20 CD | Upper Level Convention Center
Abstract 6724: OncoTwin: A multimodal digital twin framework for predicting treatment response and guiding trial design in ALK-rearranged non-small-cell lung cancer
3:05–3:20 p.m.
Presenter: Hui Xu, Ph.D.
MS.MCB09.01 — Metabolic signaling and therapeutic vulnerabilities in cancer
2:30–4:30 p.m.
Ballroom 6 CF | Upper Level Convention Center
Abstract 6803: Targeting mitochondrial complex I overcomes adaptive response to chemotherapy in advanced pancreatic cancer
2:50–3:05 p.m.
Presenter: Sergio Attanasio, Ph.D.
MS.IM02.01 — Inflammation and immunity in cancer progression
2:30–4:30 p.m.
Room 14 | Mezzanine Level Convention Center
Abstract 6788: Spatial single-cell analysis reveals stage-dependent mechanisms of anti-IL-1β therapy in lung adenocarcinoma
3:20–3:35 p.m.
Presenter: Bo Zhu, Ph.D.
ME01 — Christopher Flowers: Applying molecular classifications to therapy and trials in large b-cell lymphoma
5–5:45 p.m.
Room 5 │ Upper Level Convention Center
Speaker: Christopher Flowers, M.D.
Wednesday, April 22
PL05 — Innovative treatment modalities: Shaping the future of oncology
8–10 a.m.
Ballroom 20 | Upper Level Convention Center
Chair introduction
Speaker: Katy Rezvani, M.D., Ph.D.
Wrap-up and opportunities for the future
9:53–10 a.m.
Speaker: Katy Rezvani, M.D., Ph.D.
ADT08 — Optimizing efficacy while limiting toxicity in immunotherapy for cancer treatment
10:15–11:45 a.m.
Room 28 | Upper Level Convention Center
Migratory vs. tissue-resident leukocytes in checkpoint-induced irAEs
10:41–11:01 a.m.
Speaker: Kristen Pauken, Ph.D.
ADT09 — Targeted therapy frontiers in microsatellite-stable metastatic colorectal cancer
10:15–11:45 a.m.
Room 31 | Upper Level Convention Center
Advances and future strategies for BRAF-mutated CRC
10:20–10:40 a.m.
Speaker: Scott Kopetz, M.D., Ph.D.
AOS12 — Biology and therapeutic targeting of HIF2a in renal cell carcinoma
10:15–11:45 a.m.
Room 15 | Mezzanine Level Convention Center
A paradigm shift in Von Hippel Lindau Syndrome through HIF2a targeting
10:45–11:05 a.m.
Speaker: Eric Jonasch, M.D.
SY33 — Radioligand therapy: Immunity and biological mechanisms
10:15–11:45 a.m.
Room 16 | Mezzanine Level Convention Center
Chair Introduction
Speaker: David Piwnica-Worms, M.D., Ph.D.
Immunological considerations of RLT
10:20–10:40 a.m.
Speaker: David Piwnica-Worms, M.D., Ph.D.
PL06 — AACR Annual Meeting 2026 highlights
12:10–1:30 p.m.
Ballroom 20 | Upper Level Convention Center
Clinical research and clinical trials
12:39–1:04 p.m.
Speaker: Ecaterina Dumbrava, M.D.
Poster Sessions
Sunday, April 19
2–5 p.m.
PO.BCS02.01 - Agentic AI in cancer
Section 2
Abstract 16 (Poster Board 1): DrBioRight: An AI research assistant for cancer data analysis
Presenter: Han Liang, Ph.D.
Abstract 3 (Poster Board 16): Charles: A self-critical agentic AI drug discovery analyst for cancer
Presenter: Seyedmehdi Orouji, Ph.D.
PO.BCS01.01 - Application of bioinformatics to cancer biology 1
Section 3
Abstract 39 (Poster Board 1): Single-cell dissection of ESCC identifies targetable cells-of-origin and therapeutic vulnerabilities in early tumorigenesis
Presenter: Kyung Pil Ko, Ph.D.
Abstract 40 (Poster Board 2): Integrated transcriptomic and immune-clonal evolution defines stepwise molecular progression in lung adenocarcinoma
Presenter: Kang Qin, M.D.
Abstract 49 (Poster Board 11): The PER3-RORB axis defines a tumor-suppressive circadian state associated with improved survival in head and neck squamous cell carcinoma
Presenter: Harold Nathan Tan, M.D.
Abstract 53 (Poster Board 15): RNA fusions: An untapped source of neoantigens for immune based breast cancer prevention and treatment across all subtypes of breast cancers
Presenter: Anjana Bhardwaj, Ph.D.
Abstract 62 (Poster Board 24): Comprehensive characterization of m6A RNA methylation across human cancers
Presenter: Yining Zhao, Ph.D.
PO.IM01.07 - Alternative cell type and in situ cell therapies
Section 7
Abstract 141 (Poster Board 15): Selecting cord blood-derived NK cells enriched in mature subsets optimizes CAR-NK cell-based anti-tumor therapy
Presenter: Ye Ethan Li, M.D., Ph.D.
Abstract 142 (Poster Board 16): A universal multi-receptor NK cell platform engineered for synergistic combination with antibody and T-cell engager therapies
Presenter: Rafet Basar, M.D.
PO.IM02.01 - Inflammation and cancer progression
Section 9
Abstract 200 (Poster Board 20): Spatiotemporal analysis reveals tsMHC-I downregulation-induced neutrophil extracellular traps as a driver of lung adenocarcinoma neoplastic evolution
Presenter: Yanhua Tian, Ph.D.
PO.ET01.04 - Kinase and signaling pathway dependencies driving cancer therapeutic response
Section 14
Abstract 323 (Poster Board 8): Dual inhibition of SIK2/3 induces ER Stress and ER-phagy, enhancing the cytotoxicity of autophagy blockade in ovarian cancer
Presenter: Rumeysa Ozyurt, Ph.D.
PO.ET01.02 - Mechanism-guided development of targeted cancer therapies
Section 15
Abstract 356 (Poster Board 15): Rezatapopt and KRAS inhibitors for the treatment of TP53 Y220C and KRAS mutant cancers
Presenter: Argun Akcakanat, M.D., Ph.D.
Abstract 357 (Poster Board 16): DIRAS3 mimetic peptide achieves dual MAPK and PI3K pathway suppression across KRAS hotspot mutations
Presenter: Gamze Bildik, Ph.D.
PO.ET03.01 - Mechanisms of drug resistance 1
Section 16
Abstract 387 (Poster Board 20): Precision combination therapy opportunities in colorectal cancer revealed by PDX drug screening
Presenter: Alexey Sorokin, Ph.D.
Abstract 391 (Poster Board 24): TROP2 and PTEN are biomarkers of primary resistance to TUSC2 gene therapy in non-small cell lung cancer (NSCLC)
Presenter: Ismail M. Meraz, Ph.D.
Abstract 392 (Poster Board 25): EMT-like reprogramming drives drug-tolerant persister cell plasticity in mantle cell lymphoma via ribosome biogenesis
Presenter: Wei Wang, M.D., Ph.D.
PO.ET09.06 - Novel antitumor agents 1
Section 17
Abstract 424 (Poster Board 27): Targeting tGLI1 in breast cancer brain metastases with a novel ketoconazole derivative
Presenter: Mariana Najjar
PO.ET02.11 - Novel therapeutics and drug targets 1
Section 18
Abstract 442 (Poster Board 12): Crippling cancer’s energy and escape: NAMPT and BCL2 as dual targets in T-ALL
Presenter: John Robert Sanchez, Ph.D.
Abstract 452 (Poster Board 22): Therapeutic potential of AURKA inhibition in ER+ inflammatory breast cancer
Presenter: Tanu Sharma, Ph.D.
PO.TB05.01 - Developmental origins, drivers, and heterogeneity in pediatric cancer
Section 26
Abstract 638 (Poster Board 17): Spatial organization of epithelial- and neural-like tumor phenotypes and their cellular neighborhoods in desmoplastic small round cell tumors
Presenter: Jiaqian Fan
PO.TB09.03 - Methods to measure tumor evolution and heterogeneity
Section 28
Abstract 688 (Poster Board 4): Pan-cancer mapping of genetic immune escape evolutionary trajectories
Presenter: Shengqing Gu, Ph.D.
PO.TB10.06 - Spatial protein profiling and multi-modal mapping of tumor and circulating ecosystems
Section 32
Abstract 804 (Poster Board 16): Distinct cellular phenotypes and spatial neighborhoods constitute the heterogeneous microenvironment of desmoplastic small round cell tumor
Presenter: Kevin Murgas, Ph.D.
PO.TB07.01 - Stem cell plasticity and lineage reprogramming in cancer
Section 33
Abstract 824 (Poster Board 3): PPARδ overexpression drives transformation of multiple gastric progenitor and stem cells and tumorigenesis in mice
Presenter: Xiangsheng Zuo, M.D., Ph.D.
PO.PS01.10 - Survivorship research
Section 34
Abstract 878 (Poster Board 24): Long-term physical quality of life in survivors of adolescent and young adult Hodgkin lymphoma: Risk factors and associations with adverse health outcomes
Presenter: Carlos Cruz, M.D.
Abstract 932 (Poster Board 14): High sucrose intake amplifies and independently promotes anthracycline-induced cardiac dysfunction and senescence in juvenile mouse models
Presenter: Alaina Poche
PO.CL01.01 - Biomarkers predictive of therapeutic benefit 1
Section 40
Abstract 1009 (Poster Board 3): Landscape of homozygous copy number (CN) losses with established and emerging clinical actionability across 430,467 pan-tumor tissue samples
Presenter: Timothy Yap, M.B.B.S., Ph.D.
PO.CL01.02 - Biomarkers predictive of therapeutic benefit 2
Section 41
Abstract 1041 (Poster Board 9): Extracellular vesicle-associated noncanonical ORFs as biomarkers of surgical outcome and chemoresistance in ovarian cancer
Presenter: Sanghoon Lee, Ph.D.
PO.CL01.22 - Circulating tumor cells, metastasis, and dissemination biology 1
Section 42
Abstract 1076 (Poster Board 16): Cancer-neuron interaction initiates neural mimicry and brain colonization in EGFR-mutant NSCLC
Presenter: Sam Song, Ph.D.
Abstract 1078 (Poster Board 18): From protocol to practice: The gap in obtaining progression disease biopsies across 182 oncology trials
Presenter: Anjali Vinocha, M.D.
PO.CL01.07 - Liquid biopsies: Circulating nucleic acids 1
Section 44
Abstract 1138 (Poster Board 19): Clinical grade circulating tumor DNA methylation predicts outcome to brigatinib plus local consolidative therapy in patients with ALK rearranged NSCLC - Liquid biopsy correlates from the BRIGHTSTAR trial
Presenter: Simon Heeke, Ph.D.
PO.CL01.15 - Prognostic biomarkers 1
Section 46
Abstract 1181 (Poster Board 5): Transcriptomic analysis of NDRG1 amplification in aggressive breast cancer
Presenter: Emilly Villodre, Ph.D.
PO.CL01.12 - Spatial proteomics and transcriptomics 1
Section 47
Abstract 1201 (Poster Board 2): Spatial 3D and multi-omics mapping of diffuse gastric cancer evolution from preinvasive to invasive lesions in CDH1 mutation carriers
Presenter: Yunhe Liu, Ph.D.
Abstract 1203 (Poster Board 4): Spatial archetypes of conserved and cancer-specific immune-stromal niches
Presenter: Tian Chu, Ph.D.
PO.CL11.02 - Survivorship, supportive care, and quality of life in oncology
Section 48
Abstract 1235 (Poster Board 9): Exercise volume, skeletal muscle maintenance, and plasma IL-6/IL-6R in patients with PDAC
Presenter: Guanshu Liu
PO.CL07.03 - Targeting DNA repair, cell cycle, and tumor metabolism
Section 49
Abstract 1256 (Poster Board 1): A novel therapeutic approach to overcome metabolic reprogramming in lung cancer
Presenter: Yonathan Lissanu, M.D., Ph.D.
LBPO.IM01 - Late-breaking research: Immunology 1
Section 54
Abstract LB083 (Poster Board 9): Gut microbiome signatures of survival and immunotherapy response in advanced thyroid cancer
Presenter: Anastasios Maniakas, M.D., PhD.
Abstract LB086 (Poster Board 12): Macrophage-dendritic cell-T-cell tetrads orchestrate antitumor immunity and response to checkpoint blockade
Presenter: Mehdi Chaib, Ph.D.
Abstract LB088 (Poster Board 14): Identifying mechanisms of immune suppression in KRAS-inhibitor resistance in NSCLC
Presenter: Samrat Kundu, Ph.D.
Monday, April 20
9 a.m.–noon
PO.BCS01.02 - Application of bioinformatics to cancer biology 2
Section 3
Abstract 1423 (Poster Board 17): Aneuploidy detection from FFPE archived tissues: A computational approach for FFPE-CUTAC data
Presenter: Aditya Parmar
Abstract 1424 (Poster Board 18): Unique tumor ecosystems in metaplastic breast cancer identified through single nucleus RNA sequencing
Presenter: Aatish Thennavan, Ph.D.
PO.BCS01.07 - Digital pathology 2
Section 4
Abstract 1455 (Poster Board 18): Comparison of digital and artificial intelligence (AI)-computational algorithms for quantifying low/ultralow human epidermal growth factor receptor 2 (HER2) protein expression in metastatic breast cancer (mBC) from clinical samples
Presenter: Savitri Krishnamurthy, M.D.
PO.BCS01.09 - Integrative computational approaches 1
Section 5
Abstract 1468 (Poster Board 7): Germline whole exome sequencing implicates homologous recombination repair pathway genes as risk factors in SMARCB1 deficient renal medullary phenotypes without sickle hemoglobinopathies
Presenter: Pankaj Kumar Chauhan, Ph.D.
Abstract 1486 (Poster Board 25): From animals to computational oncology: Digital twins as ethical enablers of next-generation bone metastasis research
Presenter: Eleonora Dondossola, Ph.D.
PO.BCS01.15 - Sequence analysis
Section 6
Abstract 1495 (Poster Board 2): A novel, deep learning -based filtering tool for enhanced detection of technical artifacts in whole-genome sequencing data
Presenter: Julian Gascoyne
PO.IM02.02 - Innate immunity in cancer
Section 9
Abstract 1602 (Poster Board 23): Quaking regulates macrophage MHC II-mediated antigen presentation and immune function in glioblastoma
Presenter: Spring Yewon Hwang
PO.ET02.01 - Antibody-drug conjugates and linker engineering 1
Section 12
Abstract 1693 (Poster Board 22): Targeting MET-LGR5 crosstalk using an antibody-drug conjugate combination with diverse payloads to overcome adaptive resistance in colorectal cancer
Presenter: Shraddha Subramanian
PO.ET06.03 - DNA damage and repair 2
Section 14
Abstract 1744 (Poster Board 10): CRISPR screening identifies SMARCAL1 and MRN as modulators of WRN dependency in MSI-H colorectal cancer
Presenter: Junjie Chen, Ph.D.
PO.ET03.02 - Mechanisms of drug resistance 2
Section 16
Abstract 1799 (Poster Board 19): Ferroportin mediates bevacizumab resistance and ferroptosis evasion in ovarian cancer
Presenter: Zonghao Tan
PO.ET03.07 - Targeting drug resistance 1: Apoptosis and autophagy
Section 18
Abstract 1844 (Poster Board 4): Epigenetic rewiring of BCL6 drives responses and unveils synthetic dependencies in large B cell lymphoma
Presenter: Haopeng Yang, Ph.D.
Abstract 1860 (Poster Board 20): Determining mechanisms of ONC212-resistance in uveal melanoma to develop combination therapy strategies
Presenter: Md Alauddin, Ph.D.
PO.MCB01.01 - Cell cycle
Section 20
Abstract 1920 (Poster Board 28): Resolving telomere length dynamics in breast cancer evolution through single-cell DNA sequencing
Presenter: Nicolaas Baudoin, Ph.D.
PO.MCB06.01 - Chromatin structure and function
Section 21
Abstract 1924 (Poster Board 1): Retrotransposon reactivation to elicit innate immunity in squamous cancers while sparing normal tissues
Presenter: Yejing Ge, Ph.D.
Abstract 1941 (Poster Board 18): KMT2D loss drives gastric cancer tumorigenesis through an RCOR3-dependent mechanism
Presenter: Liyong Zeng, Ph.D.
PO.MCB06.02 - DNA methylation
Section 22
Abstract 1962 (Poster Board 14): Epigenetic remodeling of BCOR-PRC1.1 complex dictates response and resistance to IDH inhibitors in AML
Presenter: Sarah Hanache, Ph.D.
PO.TB10.05 - Aging and host determinants of tumor progression: The macroenvironmental axis
Section 26
Abstract 2085 (Poster Board 15): Novel obesity-associated adipokine modulates the malignant phenotype of endometrial cancer cells
Presenter: Chi Lam Au Yeung, Ph.D.
Abstract 2087 (Poster Board 17): Intermittent fasting remodels gut ecosystem to influence initiation and therapy responses in pancreatic cancer
Presenter: Le Li, Ph.D.
Abstract 2098 (Poster Board 28): CNTF governs exercise-induced myofibroblast reversion in prostate cancer
Presenter: Pengju Gong
PO.TB03.04 - Characterization of metastases by imaging and profiling
Section 27
Abstract 2112 (Poster Board 10): Image activated cell sorting reveals distinct morpholomic manifolds in breast cancer cell lines
Presenter: Andres Nevarez, Ph.D.
PO.TB03.01 - Therapies targeting metastasis
Section 32
Abstract 2228 (Poster Board 3): Biofield therapy inhibits pancreatic cancer invasion and metastasis by modulating multiple steps of metastatic cascade
Presenter: Peiying Yang, Ph.D.
PO.TB10.01 - Tumorigenesis and early microenvironmental trajectories
Section 33
Abstract 2253 (Poster Board 2): Multimodal and multikingdom spatial transcriptomics identify bacterial niches implicated in oral cancer development
Presenter: Fushun Chen, Ph.D.
Abstract 2255 (Poster Board 4): Spatial transcriptomics reveals evolving tumor microenvironmental archetype along the lung premalignancy-adenocarcinoma continuum
Presenter: Yibo Dai
Abstract 2259 (Poster Board 8): Reprogramming of the stromal and immune microenvironment in preinvasive breast cancer
Presenter: Siyuan He
PO.CL01.03 - Biomarkers predictive of therapeutic benefit 3
Section 40
Abstract 2446 (Poster Board 16): High PRMT5 expression is associated with decreased immune infiltrate and worse outcomes to immune checkpoint inhibitors in non-small cell lung cancer
Presenter: Natalie Vokes, M.D.
PO.CL05.05 - Immunomodulatory effects of targeted therapies
Section 45
Abstract 2559 (Poster Board 3): Identifying cancer cell intrinsic regulators of radiation-induced interferon signaling
Presenter: Olivia Kaneko
PO.CTP01.01 - Phase I clinical trials in progress
Section 51
Abstract CT091 (Poster Board 22): Trial in progress: A Phase I study of personalized neoantigen vaccination combined with PD-1 blockade and CD40 agonism in resected pancreatic ductal adenocarcinoma
Presenter: Daniel Haldar, M.D.
LBPO.IM02 - Late-breaking research: Immunology 2
Section 53
Abstract LB151 (Poster Board 16): Liposomal doxorubicin potentiates anti-tumor immune response in oral cavity squamous cell carcinoma
Presenter: Jennifer Anderson, M.D., Ph.D.
2–5 p.m.
PO.BCS01.16 - Integration of clinical and research data
Section 2
Abstract 2709 (Poster Board 2): PRECISE: A prognostic thyroid follicular cell-derived gene signature for papillary thyroid carcinoma
Presenter: Jennifer Wang, M.D., Ph.D.
Abstract 2720 (Poster Board 13): A comprehensive LLM-enabled pharmacodynamic biomarker resource to accelerate cancer drug development
Presenter: Yuntao Yang, Ph.D.
PO.BCS02.04 - Radiomics and AI in medical imaging
Section 4
Abstract 2773 (Poster Board 4): Multi-regional CT-based radiomics fusion predicts pathological pollutant index associated with lung adenocarcinoma
Presenter: Yutong Li, Ph.D.
Abstract 2774 (Poster Board 5) : Pulmonary nodule tracking in metastatic Ewing sarcoma enables personalized predictive models
Presenter: Kevin Murgas
PO.IM01.11 - Immune checkpoints
Section 7
Abstract 2807 (Poster Board 12): Immune cell-dependent resistance to LAG3 blockade in SMARCB1-deficient renal medullary carcinoma
Presenter: Jing Qian, M.D., Ph.D.
Abstract 2812 (Poster Board 17): Bhlhe40 shapes distinct T cell reponses to anti PD1 and anti CTLA4 immune checkpoint therapy
Presenter: Akata Saha, Ph.D.
PO.IM02.03 - Microbiome, inflammation, and response to immunotherapy in cancer
Section 9
Abstract 2874 (Poster Board 14): PPARδ overexpression in villin-positive gastric progenitor cells drive gastric tumorigenesis independent of helicobacter infection in mice
Presenter: Daoyan Wei, Ph.D.
Abstract 2877 (Poster Board 17): The role of oral microbiota in pre-metastatic niche preparation in the brain
Presenter: Rene Nicolas Rico
PO.IM01.02 - Modifiers of inflammation and the tumor microenvironment
Section 10
Abstract 2895 (Poster Board 5): JAK inhibition enhances virotherapy in gliomas by modulating interferon-driven resistance
Presenter: Andres Lopez-Rivas
Abstract 2917 (Poster Board 27): Novel strategies for targeting B7-H3 to empower precision oncology
Presenter: Di Zhao, Ph.D.
PO.ET05.02 - Cellular responses to anticancer drugs
Section 11
Abstract 2929 (Poster Board 6): Immune and pharmacodynamic effects of sotorasib plus panitumumab in KRAS G12C-mutant colorectal cancer: Paired biopsy results from CodeBreaK 101
Presenter: David Hong, M.D.
PO.ET03.06 - Drug resistance 1: Antibodies and ADCs
Section 12
Abstract 2959 (Poster Board 5): Improving the efficacy of B7-H3 targeting antibody-drug conjugates in TP53-deficient prostate cancer
Presenter: Javier Leo
Abstract 2970 (Poster Board 16): Limited efficacy of HER3-DXd in colorectal cancer PDX models reveals molecular resistance mechanisms and informs rational combinatorial strategies
Presenter: Preeti Kanikarla, Ph.D.
PO.ET02.12 - Novel therapeutics and drug targets 2
Section 16
Abstract 3073 (Poster Board 1): Dickkopf1 as a potential therapeutic target in highly aggressive breast cancers
Presenter: Mohd Mughees, Ph.D.
Abstract 3075 (Poster Board 3): FGFR2b is a highly prevalent and actionable cell surface target in intrahepatic cholangiocarcinoma
Presenter: Nakul Shah, M.D.
Abstract 3079 (Poster Board 7): Discovery of a novel, covalent and heterobifunctional thioredoxin reductase inhibitor with antitumor activity
Presenter: Yonathan Lissanu, M.D., Ph.D.
Abstract 3087 (Poster Board 15): Targeting AURKA and TRIP13 exploits mitotic vulnerability and enhances antitumor immunity in Rb-deficient immunocompetent lung cancer models
Presenter: Soma Ghosh, Ph.D.
PO.MCB06.03 - Epigenetic changes as molecular markers of cancer
Section 20
Abstract 3205 (Poster Board 15): Single cell DNA methylation of early breast cancer reveals epigenomic response to driver mutations and unique signatures of progression and invasion
Presenter: Ryan Mulqueen, Ph.D.
PO.MCB08.03 - Genomic profiling to understand cancer biology
Section 22
Abstract 3250 (Poster Board 15): Comparative study of human and canine nerve sheath tumors in terms of morphology, prognosis, treatment, epigenetics, transcriptomics, and genomics
Presenter: Emily Keung, M.D.
PO.MCB09.04 - Metabolic studies in brain, pediatric, and hematologic cancers
Section 23
Abstract 3275 (Poster Board 7): Dietary fiber intake modifies the bile acid metabolic profile in the DIET trial - A randomized double blinded dietary intervention study in melanoma patients receiving immunotherapy
Presenter: Yan Jiang, Ph.D.
PO.TB10.03 - Microenvironmental determinants of therapy response and resistance 1
Section 29
Abstract 3446 (Poster Board 18): Loxl2 drives neutrophil-mediated immune evasion and resistance to anti PD-1 therapy in murine melanoma
Presenter: Jiah Yang
Abstract 3451 (Poster Board 23): Single-cell transcriptomic insights into tumor and immune dynamics driving resistance to ixazomib combined with gemcitabine and doxorubicin in SMARCB1-deficient renal medullary carcinom
Presenter: Kai Yu, Ph.D.
PO.TB03.05 - Migration and invasion
Section 30
Abstract 3469 (Poster Board 8): A novel mTORC2 signaling pathway defines the pro-metastatic invadopodia network in urothelial carcinoma
Presenter: Donna Elizabeth Hansel, M.D., Ph.D.
PO.TB05.03 - Pediatric cancer genomics and epigenomics
Section 31
Abstract 3489 (Poster Board 4): EWSR1::WT1 fusion oncoprotein and the androgen receptor shape the biology of desmoplastic small round cell tumors
Presenter: Danh Truong, Ph.D.
PO.TB09.02 - Tumor evolution
Section 33
Abstract 3540 (Poster Board 16): KRASallelic imbalance reshapes tumor evolution through selective clonal outgrowth and chromosomal instability in NSCLC
Presenter: Li Zhang, Ph.D.
PO.PS01.07 - Genetic epidemiology 1: GxE, GWAS, polygenic risk scores, and post-GWAS
Section 35
Abstract 3611 (Poster Board 29): Cell-type aware transcriptome-wide association study of mammographic density phenotypes
Presenter: Joseph Rothstein
PO.CL01.04 - Biomarkers predictive of therapeutic benefit 4
Section 41
Abstract 3744 (Poster Board 16): Peripheral immune indices predict pathologic complete response and residual cancer burden in inflammatory breast cancers
Presenter: Hui Gao, Ph.D.
PO.CL01.23 - Circulating tumor cells, metastasis, and dissemination biology 2
Section 42
Abstract 3763 (Poster Board 7): CCR7 expression and spatial distribution in inflammatory breast cancer: A baseline characterization for therapeutic targeting
Presenter: Surbhi Shivhare, Ph.D.
PO.CL12.01 - Molecular classification and tumor biology in cancer
Section 46
Abstract 3884 (Poster Board 17): Multiplex immunofluorescence based spatial analysis of HER2 positive breast cancer patients treated with bintrafusp alfa: A translational pathology study
Presenter: Maria Raso, M.D.
PO.CL07.02 - Molecular targeted therapy
Section 47
Abstract 3907 (Poster Board 13): Molecular determinants of response in laparoscopically triaged advanced ovarian cancer
Presenter: Sara Corvigno
PO.CL01.13 - Spatial proteomics and transcriptomics 2
Section 49
Abstract 3953 (Poster Board 4): Assessing the role of immune aggregates as potential biomarkers of immunotherapy response in appendiceal adenocarcinoma (AA) using spatial proteomics
Presenter: Matt Lastrapes
PO.CT01.05 - Phase II and Phase III clinical trials
Section 52
Abstract CT142 (Poster Board 6): Reducing nausea and vomiting while maintaining the full potential for efficacy with spevatamig, a CLDN18.2xCD47 bispecific antibody
Presenter: Michael Overman, M.D.
LBPO.PR01 - Late-breaking research: Prevention, early detection, and interception
Section 54
Abstract LB209 (Poster Board 7): Ecological shifts, not dysbiosis: Microbiome reorganization across oral precancer-cancer spectrum
Presenter: Anastasios Maniakas, M.D., PhD.
Tuesday, April 21
9 a.m.–noon
PO.MD01.02 - AACR Project GENIE: Genomic characterization
Section 1
Abstract 4110 (Poster Board 15): Genomic vulnerabilities and clinical behavior of metaplastic breast cancer through integrated registry and GENIE analysis
Presenter: Ahmed Shatta
PO.BCS01.04 - Application of bioinformatics to cancer biology 4
Section 2
Abstract 4125 (Poster Board 5): Goblet cell appendiceal adenocarcinoma is molecularly distinct from other histologic subtypes: Insights from large-scale genomic, transcriptomic, and organoid modeling
Presenter: Saikat Chowdhury, Ph.D.
Abstract 4127 (Poster Board 7): Inferring transcriptomic programs from circulating tumor DNA methylation signatures in small cell lung cancer using RRBS and EM-seq
Presenter: Jing Wang, Ph.D.
PO.BCS02.06 - Machine learning approaches for cancer prediction
Section 5
Abstract 4229 (Poster Board 25): AI based explainable survival modeling for advanced non small cell lung cancer
Presenter: Kang Qin, M.D.
PO.IM01.12 - Immunomodulatory agents
Section 8
Abstract 4303 (Poster Board 7): Reprogramming tumor immunogenicity by targeting EGFL6 in ovarian cancer
Presenter: Weiche Wu
Abstract 4322 (Poster Board 26): Tumor treating fields (TTFields) overcome anti-PD-1 resistance in a murine lung adenocarcinoma model
Presenter: Yun Hu, Ph.D.
PO.ET01.03 - Next-generation targeted therapies directed against tumor surface antigens
Section 16
Abstract 4544 (Poster 12): Predictive biomarkers and combination strategies to overcome resistance to HER2- and TROP2-directed antibody drug conjugates with topoisomerase I inhibitor payloads in SCLC
Presenter: Kavya Ramkumar, Ph.D.
Abstract 4546 (Poster Board 14): HER2- and TROP2-antibody-drug conjugates in small cell lung cancer cell lines and 3D culture: Efficacy and role of target expression
Presenter: Jenna Gray
Abstract 4550 (Poster Board 18): Tumor cell surface targeting of high-grade neuroendocrine carcinomas
Presenter: C. Allison Stewart, Ph.D.
PO.ET08.01 - Strategies to enhance the therapeutic index of radiotherapy
Section 19
Abstract 4637 (Poster Board 14): Alpha-particle radiotherapy combined with anti-CTLA-4 synergistically overcomes radioresistance and induces local and systemic antitumor immunity in PDAC
Presenter: Marco Reis
PO.MCB09.05 - Metabolic features of thoracic and urologic cancers
Section 23
Abstract 4728 (Poster Board 1): Loss of LKB1 promotes lactate utiliaztion in KRAS-mutant lung adenocarcinoma
Presenter: Yu Qian, Ph.D.
Abstract 4740 (Poster Board 13): Exploiting ketone body metabolism as a therapeutic vulnerability in prostate cancer
Presenter: Pablo Sanchis, Ph.D.
PO.TB04.03 - In Vitro models 2: 2D, 3D, organoids, and spheroids
Section 28
Abstract 4858 (Poster Board 7): Combined pan and precision targeting in extrachromosomal DNA-positive gastric cancer
Presenter: Gengyi Zou, M.D., Ph.D.
PO.TB10.14 - Microbiome-tumor-immune crosstalk
Section 29
Abstract 4900 (Poster Board 16): Microbiome derived lactate promotes immunosuppression and radiation resistance
Presenter: Christy Charles, Ph.D.
Abstract 4908 (Poster Board 24): Functional interrogation of pancreatic cancer resident microbes reveals their role in host modulation
Presenter: Vidhi Chandra
PO.TB10.08 - Spatial niches and functional boundaries within the tumor microenvironment 1
Section 31
Abstract 4947 (Poster Board 4): Spatially organized transcriptional programs and tumor-stroma interfaces shape immunotherapy response in microsatellite instability-high gastrointestinal cancers
Presenter: Xueshuai Han
PO.PS01.06 - Diet, alcohol, and tobacco, and other lifestyle factors
Section 35
Abstract 5037 (Poster Board 10): Liquid and solid fructose intake and colorectal cancer mortality by physical activity in U.S. prospective cohorts
Presenter: Hanseul Kim, Ph.D.
PO.CL05.02 - Adoptive Cell Therapy 2
Section 40
Abstract 5187 (Poster Board 5): IL-21-Enhanced NK cells: A mitochondrial fitness enhancement for targeting glioblastoma stem cells
Presenter: Mayra Shanley, Ph.D.
Abstract 5194 (Poster Board 12): Oncolytic virus infected tumors drive AP-1 and IRF signaling in NK cells to sustain anti tumor activity
Presenter: Hila Shaim, M.D., Ph.D.
Abstract 5197 (Poster Board 15): Metabolically supercharged NK cells engineered with adenoviral E4ORF-1
Presenter: May Daher, M.D.
Abstract 5199 (Poster Board 17): uPAR-targeting CAR-NK cells enhance cytotoxicity against acute myeloid leukemia
Presenter: Xingliang Guo
Abstract 5204 (Poster Board 22): CD5-directed CAR5/IL-15 NK cells as a therapeutic platform for T-cell malignancies
Presenter: Sunil Acharya, Ph.D.
Abstract 5206 (Poster Board 24): Mitochondrial remodeling sustains CAR-NK stemness for superior tumor control
Presenter: Silvia Tiberti, Ph.D.
PO.CL01.05 - Biomarkers predictive of therapeutic benefit 5
Section 42
Abstract 5249 (Poster Board 15): Longitudinal liquid biopsy identifies an early predictive biomarker of immune checkpoint blockade response in head and neck squamous cell carcinoma
Presenter: Robert Saddawi-Konefka, M.D., Ph.D.
PO.CL08.02 - Effects of ionizing radiation on normal tissues and FLASH radiation research
Section 43
Abstract 5265 (Poster Board 2): FLASH radiotherapy improves survival in mouse glioblastoma and spares circulating antigen reactive CD8+T-cells
Presenter: Yanxia Ma, Ph.D.
PO.CL12.03 - Epigenetics, cytogenetics, and clinical molecular genetics
Section 44
Abstract 5286 (Poster Board 6): Molecular and immune landscape of HER2-amplified colorectal cancer
Presenter: Sunyoung Lee, M.D., Ph.D.
PO.CL09.01 - Precision oncology and real world data
Section 46
Abstract 5336 (Poster Board 4): Distinct KRAS mutation codons differentially associate with microsatellite instability in colorectal carcinoma
Presenter: J. Bryan, M.D.
PO.CT01.03 - Phase I clinical trials
Section 50
Abstract CT188 (Poster Board 10): Intralesional PD-1 blockade for oral cancer prevention: First-in-class Phase I trial
Presenter: Moran Amit, M.D., Ph.D.
PO.CTP01.03 - Phase II and Phase III clinical trials in progress
Section 51
Abstract CT206 (Poster Board 1): Larotrectinib (L) in patients (pts) with solid tumors with NTRK1/2/3 amplification (amp): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study
Presenter: Jordi Rodon, M.D., Ph.D.
Abstract CT215 (Poster Board 10): RASolve 301: A Phase III study of daraxonrasib (RMC-6236) vs. docetaxel in patients with previously treated RAS-mutant NSCLC
Presenter: Ferdinandos Skoulidis, M.D., Ph.D.
LBPO.MCB02 - Late-breaking research: Molecular/cellular biology and genetics 2
Section 54
Abstract LB280 (Poster Board 5): PDIA4-NF-κB signaling mediates soluble E-cadherin-driven inflammatory breast cancer progression
Presenter: Xiaoding Hu, M.D., Ph.D.
Abstract LB285 (Poster Board 10): RASH3D19 mediates RAS pathway activation and adaptive resistance to KRAS targeting drugs in cancer
Presenter: Warapen Treekitkarnmongkol, Ph.D.
Abstract LB296 (Poster Board 21): RNA structure-targeted inhibition suppresses glioblastoma growth in human cerebral organoids
Presenter: Maria-Ancuta Jurj, Ph.D.
2–5 p.m.
PO.BCS01.05 - Application of bioinformatics to cancer biology 5
Section 1
Abstract 5451 (Poster Board 18): Omicology: A comprehensive AI/LLM/NLP-based web resource for the ontology, phylogeny, and practical navigation of omics literature
Presenter: John Weinstein, M.D., Ph.D.
PO.BCS01.12 - New software tools for data analysis
Section 4
Abstract 5505 (Poster Board 10): A unified framework for cross-platform spatial omics analysis and deep spatial profiling
Presenter: Yunhe Liu, Ph.D.
PO.IM01.08 - TCR and autologous T cell therapies
Section 9
Abstract 5623 (Poster Board 15): Novel mechanism for eliminating tumor collagens to boost efficacy by attIL12-TIL therapy in PDX sarcoma models
Presenter: Jiemiao Hu, Ph.D.
PO.ET06.01 - Cell death pathways and treatment
Section 11
Abstract 5673 (Poster Board 11): Ferroptosis induction synergizes with KRAS inhibitors in KRAS-mutant lung adenocarcinoma
Presenter: Amirali Karimi, M.D.
PO.ET05.01 - Mechanisms of anticancer drug action
Section 12
Abstract 5688 (Poster Board 4): Synthetic lethal targeting of TRIP13 and Aurora A induces mitotic DNA damage and concurrent pyroptotic-apoptotic cell death in Rb-deficient cancer cells
Presenter: Lacin Yapindi
PO.ET09.05 - Multi-axis antineoplastic agents
Section 14
Abstract 5769 (Poster Board 27): A potent TOP2 poison with robust preclinical efficacy and a favorable therapeutic window supporting clinical evaluation in pancreatic cancer
Presenter: Waldemar Priebe, Ph.D.
PO.MCB08.04 - Genetic and transcriptomic dissection of cancer evolution
Section 21
Abstract 5931 (Poster Board 19): Modeling of bladder cancer evolution from field effects by multi-platform spatial mapping on the whole-organ scale
Presenter: Bogdan Czerniak, M.D., Ph.D.
PO.MCB03.01 - RAS/MAPK signaling, KRAS targeting, and adaptive resistance
Section 23
Abstract 5985 (Poster Board 10): GNASR201C enhances peritoneal carcinomatosis in KRASG12D-driven gastrointestinal cancer models
Presenter: Ichiaki Ito
PO.MCB04.02 - Senescence and cell stress
Section 24
Abstract 6015 (Poster Board 16): Senescence-associated secretory phenotype drives PGCC‘s lifecycles and blastomere-like reprogramming to promote therapeutic resistance
Presenter: Jinsong Liu, M.D., Ph.D.
PO.TB10.11 - Fibroblasts as architects of the tumor microenvironment
Section 25
Abstract 6024 (Poster Board 1): Decoding new mechanisms of stromal-driven inflammation in breast cancer
Presenter: Fernanda Kugeratsk, Ph.D.
PO.TB04.04 - In Vivo models 2: Genetically engineered mouse models, PDXs, syngeneic models
Section 26
Abstract 6070 (Poster Board 16): Clinical and genomic determinants of PDX engraftment across solid tumors
Presenter: Leva Gorji, M.D.
Abstract 6078 (Poster Board 24): Integrating patient-derived systems to model metastatic prostate cancer and decode therapy resistance
Presenter: Agustina Sabater
PO.TB10.02 - Metastasis and organ-specific microenvironmental evolution
Section 28
Abstract 6116 (Poster Board 7): Spatial multi-omics dissection of colorectal cancer micrometastasis
Presenter: Yang Liu, Ph.D.
PO.TB03.06 - Metastatic niches and microenvironment
Section 29
Abstract 6157 (Poster Board 15): Single-cell characterization of tumor niches driving liver metastasis in colorectal cancer
Presenter: Jinho Jang, Ph.D.
Abstract 6159 (Poster Board 17): Co-evolution of cancer cells and their microenvironment of primary and lymph node metastatic prostate cancer under androgen deprivation therapy
Presenter: Ping Xu
PO.TB10.07 - Spatial Niches and Functional Boundaries within the Tumor Microenvironment 2
Section 31
Abstract 6188 (Poster Board 2): Decoding the archetypes and ecotypes of triple-negative breast cancer in responses to chemotherapy
Presenter: Yun Yan, Ph.D.
Abstract 6189 (Poster Board 3): ERBB2 expression and the immune landscape shape the tumor microenvironment and influence prognosis in esophageal adenocarcinoma brain metastases
Presenter: Nora Lawson
PO.TB10.13 - Tumor-neuron interactions and neuro-regulation of cancer
Section 32
Abstract 6229 (Poster Board 10): Neighborhood analyses in nerve fiber-associated tumor regions in hereditary diffuse gastric cancer
Presenter: Idania Carolina Lubo Julio
PO.CL05.06 - Clinical correlates of immunotherapy
Section 41
Abstract 6458 (Poster Board 6): Harnessing tumor-informed B cell receptors for discovery and antibody-based immunotherapy in sarcoma
Presenter: Varshini Arunkumar
Abstract 6473 (Poster Board 21): Clonal consolidation and transcriptional re-programming define non-small cell lung cancers resistant to immune checkpoint inhibitors
Presenter: Natalie Vokes, M.D.
Abstract 6479 (Poster Board 27): Immunotherapy and microbiota interventions as potential treatment options for anaplastic thyroid cancer
Presenter: Jocelynn Colunga Minutti
PO.CL07.04 - Combination targeted therapy
Section 42
Abstract 6484 (Poster Board 2): Divergent roles of SPOP and CHD1 in ACSL4 regulation reveal context-dependent vulnerabilities for targeting ferroptosis in prostate cancer
Presenter: Feiyu Chen, Ph.D.
PO.CL01.21 - Diagnostic biomarkers 2
Section 43
Abstract 6522 (Poster Board 11): Novel serum biomarkers that detect ovarian cancer recurrence earlier than CA125
Presenter: Cuipeng Qiu, Ph.D.
PO.CL05.09 - Inflammation, immunity, and cancer
Section 45
Abstract 6593 (Poster Board 26): B-cell guided inflammatory cascade perpetuates ICI-mediated colitis
Presenter: Roza Nurieva, Ph.D.
PO.CL08.01 - Radiation and Photodynamic Therapy Response Modifiers
Section 46
Abstract 6609 (Poster Board 10): Targeting pancreatic cancer with combination RAS inhibition and radiation therapy
Presenter: Candise Tat
Abstract 6611 (Poster Board 12): Ferroptotic vulnerability in M1 and M2 macrophages is associated with adaptive radiation resistance in esophageal adenocarcinoma
Presenter: Sadhna Aggarwal, Ph.D.
PO.CL05.13 - Vaccines and other immunomodulatory agents
Section 49
Abstract 6704 (Poster Board 15): Exercise attenuates anti-PD-1-induced adventitial macrophage inflammation in the aorta of aged melanoma-bearing mice
Presenter: Jonghae Lee, Ph.D.
PO.CT01.04 - Phase II clinical trials
Section 50
Abstract CT238 (Poster Board 3): Intratumoral sotigalimab with pembrolizumab induces rapid activation of antigen presenting cells and drives anti-tumor responses in non-injected tumors in metastatic melanoma: A Phase I/II study
Presenter: Salah-Eddine Bentebibel, Ph.D.
PO.CTP01.02 - Phase I and Phase II clinical trials in progress
Section 51
Abstract CT277 (Poster Board 11): IvoLoC Trial: A Phase II trial evaluating the efficacy of ivonescimab in metastatic endocrine refractory HR-positive HER2-negative or triple negative invasive lobular carcinoma (ILC)
Presenter: Jason Mouabbi, M.D.
Abstract CT279 (Poster Board 13): A Phase II multicohort study to evaluate lorigerlimab (PD-1 x CTLA-4) in participants with advanced solid tumors
Presenter: Helen Clark, M.D.
Abstract CT287 (Poster Board 21): A first-in-human (FIH), Phase I/II, dose-escalation and dose-optimization study of central nervous system (CNS)-penetrant, PARP1-selective inhibitor EIK1004 in patients with advanced solid tumors with or without brain metastases
Presenter: Timothy Yap, M.B.B.S., Ph.D.
Abstract CT294 (Poster Board 28): Phase I study of TROP2 CAR engineered IL-15-transduced cord blood-derived NK cells in advanced solid tumors (TROPIKANA)
Presenter: Oriol Mirallas
Wednesday, April 22
9 a.m.–noon
PO.BCS01.14 - Network biology and precision medicine
Section 3
Abstract 6863 (Poster Board 7): Integrating computational and experimental approaches to optimize RNA fusion identification in BRCA associated breast cancer
Presenter: Janvi Sandhu
Abstract 6866 (Poster Board 10): Mapping cancer-relevant genetic interactions with functional module prediction and in4mer enCas12a platform
Presenter: Chenchu Lin, Ph.D.
PO.BCS01.13 - New algorithms and computational methods
Section 4
Abstract 6894 (Poster Board 7): Predict, perturb, and process: A systems biology pipeline for identifying synthetic lethality
Presenter: Juihsuan Chou
PO.IM02.05 - Tumor-induced immune suppression
Section 9
Abstract 6989 (Poster Board 1): RBM10 loss promotes KRAS-mutant non-small cell lung cancer immune tolerance and PD-1 inhibitor resistance via a non-canonical STING/ NF-κB axis
Presenter: Minh Truong Do, Ph.D.
PO.ET03.05 - Drug resistance 2: Tyrosine kinase inhibitors
Section 11
Abstract 7025 (Poster Board 4): Mechanisms of zongertinib resistance in HER2-mutant non-small cell lung cancer and potential strategies to overcome resistance
Presenter: Yuji Shibata, M.D., Ph.D.
Abstract 7027 (Poster Board 6): Multi-lineage evolution of drug resistance via a novel keratin 17+ drug tolerant persister population in EGFR-mutant NSCLC
Presenter: Benjamin Morris, Ph.D.
PO.ET03.03 - Novel strategies to reverse drug resistance
Section 14
Abstract 7113 (Poster Board 2): Targeting breast cancer brain metastasis through novel combination of FDA-approved orally active BBB-permeable RET and tGLI1 inhibitors
Presenter: Joshua Cha
Abstract 7130 (Poster Board 19): GRN-300 restores PARP inhibitor sensitivity through inhibition of the HDAC-MEF2A-RAD51 pathway in BRCA2-revertant ovarian cancer
Presenter: Carlos Flores Suarez, Ph.D.
PO.ET01.05 - Overcoming microenvironmental and delivery barriers in cancer therapy
Section 15
Abstract 7148 (Poster Board 5): Stress adaptation defines therapeutic response to CDK4/6 inhibitors in sarcoma
Presenter: Jlenia Guarnerio, Ph.D.
PO.ET08.03 - Targeted radiopharmaceuticals and combination strategies in cancer therapy
Section 17
Abstract 7194 (Poster Board 13): Inhibiting glutamine metabolism in combination with radiation disrupts mitochondrial function and impairs homologous recombination
Presenter: Scott Bright, Ph.D.
PO.MCB08.05 - Genomic approaches to define tumor biology and clinical stratification
Section 21
Abstract 7264 (Poster Board 4): Molecular differences between ovarian and uterine carcinosarcomas
Presenter: Kwong-Kwok Wong, Ph.D.
PO.MCB04.01 - Hypoxic and proteotoxic stress response
Section 22
Abstract 7297 (Poster Board 9): HIF-1α pathway is a therapeutic vulnerability in mucinous colorectal cancer
Presenter: Yoojeong Seo, Ph.D.
PO.MCB09.02 - Metabolic vulnerabilities in pancreatic, hepatic, and renal cancers
Section 23
Abstract 7316 (Poster Board 2): Targeting sulfatide metabolism as a therapeutic vulnerability in pancreatic pre-cancer lesions
Presenter: Riccardo Ballarò, Ph.D.
PO.TB10.04 - Microenvironmental determinants of therapy response and resistance 2
Section 28
Abstract 7417 (Poster Board 1): Immune system state shapes clinical response to CAR-T therapy in mantle cell lymphoma
Presenter: Vivian Jiang, Ph.D.
Abstract 7429 (Poster Board 13): Characterizing the spatial tumor microenvironments of therapy-induced and hereditary mismatch-repair-deficient hypermutated gliomas
Presenter: Chae Yun (Kate) Cho
Abstract 7432 (Poster Board 16): Spatial protein profiling of irradiated ER positive breast cancer lymph nodes suggests nodal irradiation modulates immune function
Presenter: Elizve Barrientos-Toro, M.B.B.S.
Abstract 7438 (Poster Board 22): Residual disease on a dish: A practical approach to deep intrinsic resistance in melanoma
Presenter: Balraj Singh, Ph.D.
PO.TB10.16 - Therapeutic modulation of the tumor microenvironment: New targets and approaches 2
Section 29
Abstract 7476 (Poster Board 27): Role of AOC1 in modulating the ovarian cancer tumor microenvironment and malignant phenotype
Presenter: Sammy Ferri-Borgogno, Ph.D.
Abstract 7641 (Poster Board 28): Decoding the spatial architecture of the immune microenvironment in mismatch repair-deficient colorectal carcinogenesis
Presenter: Abel Martel-Martel, Ph.D.
PO.CL05.07 - Immune response to therapies
Section 42
Abstract 7746 (Poster Board 6): CEACAM5/6+ cancer cell and IL1B+ macrophage-mediated resistance in anti-PD-1 treated gastric cancer
Presenter: Liudeng Zhang
Abstract 7750 (Poster Board 10): Integration of spatial single cell proteomics and spatial metabolomics reveals tumor microenvironment predictive of immunotherapy response in mucosal melanoma
Presenter: Jun Wang, Ph.D.
PO.CL06.01 - Immunotherapies in pediatric cancers
Section 44
Abstract 7813 (Poster Board 16): Antitumor activity of a B7-H3 antibody-drug conjugate in osteosarcoma patient-derived and metastatic models
Presenter: Adil Bahadir, M.D.
PO.CL06.03 - Targeted therapies, predispositions, and survivorship in pediatric cancers
Section 47
Abstract 7873 (Poster Board 4): In vivo preclinical efficacy of a novel “payload-bearing” peptide LX-101 targeting IGF-1R in Ewing sarcoma
Presenter: Roberto Cardenas-Zuniga, Ph.D.
Abstract 7874 (Poster Board 5): Dose-response efficacy of cell adhesion molecule 1 (CADM1)-GGFG-Exatecan vs CADM1-PEG3-VC-Exatecan in preclinical osteosarcoma models
Presenter: Zhongting Zhang
Abstract 7883 (Poster Board 14): Surface CADM1 (Cell Adhesion Molecule 1) abundance predicts payload delivery and in-vitro efficacy of CADM1-GGFG-Exatecan ADC in osteosarcoma, aiding optimal candidate selection
Presenter: Caterina Longo, M.D.
PO.CL05.10 - Tumor microenvironment modulators
Section 49
Abstract 7953 (Poster Board 28): Engineered IL7/IL15 secreting iPSC-derived mesenchymal stromal cells convert the immunosuppressive into immune-activated tumor microenvironments (TME) and potentiate antitumor immunity
Presenter: Michael Andreeff, M.D., Ph.D.
LBPO.CL04 - Late-breaking research: Clinical research 4
Section 51
Abstract LB429 (Poster Board 19): Impact of severe liver metastases on clinical response to immunotherapy in solid tumors
Presenter: Aung Naing, M.D.
LBPO.TB03 - Late-breaking research: Tumor biology 3
Section 54
Abstract LB485 (Poster Board 4): Integrative analyses of cervical cancer and patient-derived organoids uncover signaling and metabolic circuits associated with therapy-resistant
Presenter: Jennifer Wang, M.D., Ph.D.
Abstract LB497 (Poster Board 16): Portraits of clonal landscape and mutational signature in primary tumors and matched lung metastatic model of osteosarcoma
Presenter: Sylvester Jusu, Ph.D.
Give Now
Your gift will help make a tremendous difference.
Research Areas
Find out about the four types of research taking place at UT MD Anderson.
Subscribe
Get the latest information on our cancer breakthroughs.